Gouvernance Agios Pharmaceuticals, Inc.

AGIO

US00847X1046

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 31/08/2026			Varia. 5j.	Varia. 1 janv.
33,68 ^USD	+1,08%		+3,19%	+23,73%

30/07	Transcript : Agios Pharmaceuticals, Inc., Q2 2026 Earnings Call, Jul 30, 2026
30/07	Agios Pharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Comité Exécutif: Agios Pharmaceuticals, Inc.

Dirigeant

Fonctions occupéesDepuis

Brian Goff

57 ans

Chief Executive Officer

08/08/2022

Jim Burns

48 ans

General Counsel

01/01/2016

Cecilia Jones

51 ans

Director of Finance/CFO

26/09/2022

Ellen Lopresti

Human Resources Officer

01/01/2022

Sarah Gheuens

47 ans

Chief Tech/Sci/R&D Officer

01/09/2021

T. Washburn

45 ans

Comptroller/Controller/Auditor

Clive Patience

62 ans

Chief Tech/Sci/R&D Officer

01/01/2022

Morgan Sanford

Investor Relations Contact

Composition du Conseil d'Administration: Agios Pharmaceuticals, Inc.

Administrateur

ComitésDepuis

Jacqualyn Fouse

64 ans

Audit Committee	01/07/2025
Finance Committee
Governance Committee	01/07/2025
Nominating Committee	01/07/2025
Compensation Committee

Kaye Foster-Cheek

66 ans

Compensation Committee	24/05/2023
HR Committee
Governance Committee Chair	09/12/2014
Nominating Committee Chair	09/12/2014
Compensation Committee Chair

Brian Goff

57 ans

Governance Committee	01/04/2025
Nominating Committee	01/04/2025
Compensation Committee Chair	01/01/2025
HR Committee Chair	01/01/2025

Cynthia Smith

57 ans

Compensation Committee Chair	24/05/2023
HR Committee Chair	24/05/2023
Governance Committee Chair	15/04/2025
Nominating Committee Chair	15/04/2025

David Scadden

73 ans

Governance Committee	01/06/2022
Nominating Committee	01/06/2022
Compensation Committee	06/02/2019

May Kin Ho

73 ans

Audit Committee	01/03/2018
Governance Committee	01/04/2021
Nominating Committee	01/04/2021

Jeffrey Capello

61 ans

Audit Committee	12/09/2022
Compensation Committee	12/09/2022
Audit Committee Chair

Catherine Adams

55 ans

Compensation Committee	13/06/2023
HR Committee	13/06/2023

Rahul Ballal

48 ans

Audit Committee

Jay Backstrom

71 ans

Director/Board Member	08/07/2025
Independent Dir/Board Member	08/07/2025

Dernières Nominations: Agios Pharmaceuticals, Inc.

23/04	Santhera Pharmaceuticals Holding AG annonce un changement de Direction Générale	CI
05/01	Compass Therapeutics, Inc. annonce des nominations à des postes de direction, effectives au 1 ^er janvier 2026	CI
15/09/25	Atavistik Bio nomme Susan Pandya, M.D., au poste de Directrice Médicale	CI
08/07/25	Agios Pharmaceuticals nomme Jay Backstrom au Conseil d'administration et au Comité Science et Technologie	CI
08/07/25	Agios nomme le Dr Jay Backstrom au conseil d'administration	RE
13/02/25	Agios Pharmaceuticals, Inc. annonce la démission de David P. Schenkein, M.D., du conseil d'administration et du comité scientifique et technologique, à compter du 28 février 2025.	CI
20/11/24	C4 Therapeutics, Inc. nomme Steve Hoerter au conseil d'administration	CI

Plus d'Actualités

Anciens Dirigeants et Administrateurs: Agios Pharmaceuticals, Inc.

Insider

Fonctions occupées

DepuisJusqu'au

Christopher Taylor

Investor Relations Contact	-	01/08/2025
Public Communications Contact	-	01/08/2025

David Schenkein

Director/Board Member	08/08/2022	28/02/2025
Chief Executive Officer	01/08/2009	01/02/2019
Chairman	01/02/2019	08/08/2022
Independent Dir/Board Member	08/08/2022	28/02/2025
President	01/08/2009	01/02/2019

Paul Clancy

Director/Board Member	24/09/2013	13/06/2023
Independent Dir/Board Member	24/09/2013	13/06/2023

John Maraganore

Director/Board Member	01/02/2019	24/05/2023
Chairman	26/08/2016	01/02/2019
Independent Dir/Board Member	01/02/2019	24/05/2023

Holly Manning

Investor Relations Contact	-	-
Public Communications Contact	01/01/2017	-

Jessica Rennekamp

Public Communications Contact

01/12/2019

01/04/2023

Richa Poddar

Corporate Officer/Principal

01/01/2016

31/12/2022

Jonathan Biller

Director of Finance/CFO	11/09/2020	16/09/2022
General Counsel	01/11/2019	16/09/2022

Bruce Car

Chief Tech/Sci/R&D Officer

06/01/2020

01/08/2022

Ian Clark

Director/Board Member	01/12/2016	25/04/2022
Independent Dir/Board Member	01/12/2016	25/04/2022

Charlie Newman

Corporate Officer/Principal

01/01/2022

Melissa McLaughlin

Human Resources Officer

01/01/2015

01/01/2022

Darrin Miles

Corporate Officer/Principal	25/02/2021	06/12/2021
Sales & Marketing	02/04/2019	25/02/2021

Christopher Bowden

Chief Tech/Sci/R&D Officer

14/05/2014

01/09/2021

Carman Alenson

Comptroller/Controller/Auditor

07/11/2016

30/07/2021

Susan Pandya

Corporate Officer/Principal

01/04/2021

Orlando Oliveira

Corporate Officer/Principal

01/08/2019

01/01/2021

Andrew Hirsch

Director of Finance/CFO

19/09/2016

11/09/2020

Meredith Goldwasser

Corporate Officer/Principal

01/11/2017

01/09/2020

Jacqueline Cinicola

General Counsel

01/06/2013

01/07/2020

Scott Biller

Chief Tech/Sci/R&D Officer

01/09/2010

31/12/2019

Thomas-Christian Mix

Corporate Officer/Principal

01/05/2018

01/10/2019

Christiane Langer

Corporate Officer/Principal

01/05/2016

01/04/2019

Steven Hoerter

Corporate Officer/Principal

01/12/2016

01/03/2019

Eyal Attar

Chief Tech/Sci/R&D Officer

01/01/2014

01/01/2019

Renee T. Leck

Public Communications Contact

01/05/2015

01/12/2018

Min Wang

General Counsel	01/02/2010	01/11/2018
Corporate Secretary	01/02/2010	01/11/2018

Samuel Agresta

Chief Tech/Sci/R&D Officer

01/12/2011

01/08/2018

Kevin Marks

Corporate Officer/Principal

01/09/2016

01/04/2018

Lewis Cantley

Director/Board Member	01/01/2008	31/12/2017
Founder	07/08/2007	31/12/2017

Ann J. Barbier

Corporate Officer/Principal

01/06/2015

01/10/2017

Robert Sheroff

Chief Tech/Sci/R&D Officer

01/06/2015

30/06/2017

Robert Nelsen

Director/Board Member	01/12/2007	01/06/2017
Independent Dir/Board Member	-	01/06/2017

John Evans

Corporate Officer/Principal

03/05/2012

01/04/2017

Douglas Cole

Director/Board Member

01/12/2007

02/01/2017

Marion Dorsch

Corporate Officer/Principal

01/04/2012

01/11/2016

Glenn Goddard

Director of Finance/CFO	01/07/2010	19/09/2016
Public Communications Contact	01/07/2010	30/09/2016

Marc Tessier-Lavigne

Director/Board Member	22/09/2011	23/06/2015
Chairman	23/06/2015	26/08/2016
Independent Dir/Board Member	12/06/2013	26/08/2016

Perry Karsen

Director/Board Member	01/11/2011	01/03/2016
Independent Dir/Board Member	01/11/2011	21/05/2014

John Higgons

Chief Operating Officer

13/01/2010

15/01/2016

Kevin Starr

Director/Board Member	13/01/2010	16/03/2015
Chief Executive Officer	01/06/2008	13/01/2010
Chairman	16/03/2015	23/06/2015
Independent Dir/Board Member	21/05/2014	23/06/2015

Megan E. Pace

Public Communications Contact	01/02/2015	-
Corporate Officer/Principal	01/02/2015	-

Camille Henderson

Human Resources Officer

01/01/2010

01/03/2014

Robert J. DeVita

Corporate Officer/Principal

03/05/2012

Craig Thompson

Founder

07/08/2007

13/01/2010

Shin-San Su

Founder	07/08/2007	-
Corporate Officer/Principal	17/06/2013	-

Tak-Wah Mak

Founder

07/08/2007

Nirupama Subramanian

Corporate Officer/Principal

Lou Tartaglia

Chief Tech/Sci/R&D Officer

07/08/2007

Lora L. Pike

Investor Relations Contact	-	-
Public Communications Contact	-	-

Samantha Bender

Corporate Officer/Principal

Katie Dahlstrom

Chief Tech/Sci/R&D Officer

Nick Leschly

Corporate Officer/Principal

Dan Budwick

Public Communications Contact

Alexandra Balcom

Comptroller/Controller/Auditor

Kendra Adams

Investor Relations Contact	-	-
Public Communications Contact	-	-

Jake Bauer

Corporate Officer/Principal

David W. White

Corporate Officer/Principal

Francesco G. Salituro

Corporate Officer/Principal

Tanja Weber

Corporate Officer/Principal

Jeff Saunders

Corporate Officer/Principal

Helen Ho

Corporate Officer/Principal

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	15
Femme	6

Dont comité exécutif

Homme	6
Femme	2

Dont Administrateurs

Homme	7
Femme	3

Révisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Non

Controverses sur les droits de l'Homme

Non

Controverses Subventions fiscales

Non

Conforme à la finance Islamique

Agios Pharmaceuticals, Inc. est une société biopharmaceutique. La société se consacre au développement et à la mise à disposition de traitements innovants destinés aux patients atteints de maladies rares. Elle commercialise un activateur de la pyruvate kinase (PK) de première génération destiné aux adultes présentant un déficit en PK, le premier traitement modificateur de la maladie pour l'anémie hémolytique invalidante. Le principal produit candidat de son portefeuille, PYRUKYND (mitapivat), est un activateur des enzymes pyruvate kinase (PK) de type sauvage et mutantes, destiné au traitement potentiel des anémies hémolytiques. Elle développe également le tebapivat, un nouvel activateur de la PK, pour le traitement potentiel des syndromes myélodysplasiques à faible risque (SMD-FR) et des anémies hémolytiques ; l'AG-181, son stabilisateur de la phénylalanine hydroxylase (PAH), destiné au traitement potentiel de la phénylcétonurie (PCU) ; et l'AG-236, un ARNsi sous licence d'Alnylam Pharmaceuticals, Inc., ciblant le gène de la sérine protéase transmembranaire 6 (TMPRSS6) pour le traitement potentiel de la polycythémie vraie (PV).

Employés

540

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société